Related Experiment Video
Updated: Oct 17, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Pantoprazole Attenuates MAPK (ERK1/2, JNK, p38)-NF-κB and Apoptosis Signaling Pathways after Renal
Michael A Fawzy1, Sherif A Maher2, Sally M Bakkar3
1Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Abstract:
Ischemia/reperfusion injury (IRI) in the kidney is the most common cause of acute renal dysfunction through different cell damage mechanisms. This study aimed to investigate, on molecular basics for the first time, the effect of pantoprazole on renal IRI in rats. Different biochemical parameters and oxidative stress markers were assessed. ELISA was used to estimate proinflammatory cytokines. qRT-PCR and western blot were used to investigate the gene and protein expression. Renal histopathological examination was also performed. IRI resulted in tissue damage, elevation of serum levels of creatinine, urea nitrogen, malondialdehyde, TNF-α, IL-6, IL-1β, up-regulation of NF-κB, JNK1/2, ERK1/2, p38, and cleaved caspase-3 proteins. Furthermore, it up-regulated the expression of the Bax gene and down-regulated the expression of the Bcl-2 gene. Treatment of the injured rats with pantoprazole, either single dose or multiple doses, significantly alleviated IRI-induced biochemical and histopathological changes, attenuated the levels of proinflammatory cytokines, down-regulated the expression of NF-κB, JNK1/2, ERK1/2, p38, and cleaved caspase-3 proteins, and the Bax gene, and up-regulated Bcl-2 gene expression. Moreover, treatment with pantoprazole multiple doses has an ameliorative effect that is greater than pantoprazole single-dose. In conclusion, pantoprazole diminished renal IRI via suppression of apoptosis, attenuation of the pro-inflammatory cytokines' levels, and inhibition of the intracellular signaling pathway MAPK (ERK1/2, JNK, p38)-NF-κB.
Insights
Pantoprazole effectively mitigates kidney injury caused by ischemia/reperfusion (IRI) by reducing inflammation and apoptosis. Multiple doses showed greater protective effects against renal damage in rats.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Background:
- Kidney ischemia/reperfusion injury (IRI) is a primary cause of acute kidney dysfunction.
- Understanding the molecular mechanisms of IRI is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the molecular effects of pantoprazole on renal IRI in a rat model.
- To elucidate the protective mechanisms of pantoprazole against IRI-induced kidney damage.
Main Methods:
- Assessment of biochemical parameters and oxidative stress markers.
- Quantification of proinflammatory cytokines using ELISA.
- Analysis of gene and protein expression via qRT-PCR and Western blot.
- Histopathological examination of kidney tissue.
Main Results:
- IRI induced significant kidney damage, elevated serum creatinine, urea nitrogen, and malondialdehyde.
- IRI led to increased levels of TNF-α, IL-6, IL-1β, and upregulated NF-κB, JNK1/2, ERK1/2, p38, and cleaved caspase-3.
- Pantoprazole treatment ameliorated IRI-induced damage, reduced inflammation, and modulated apoptosis-related gene/protein expression (Bax, Bcl-2).
- Multiple doses of pantoprazole demonstrated superior protective effects compared to a single dose.
Conclusions:
- Pantoprazole effectively diminishes renal IRI by suppressing apoptosis.
- Pantoprazole attenuates pro-inflammatory cytokine levels and inhibits the MAPK (ERK1/2, JNK, p38)-NF-κB signaling pathway.
- The findings highlight pantoprazole's therapeutic potential in managing kidney IRI.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Related Concept Videos
MAPK Signaling Cascades
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System